Biotechnology

Larimar Therapeutics

Larimar Therapeutics released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.328 (forecast USD -0.5357)

Larimar Therapeutics released FY2025 Q4 earnings on March 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7336 (forecast USD -0.51)

Larimar Therapeutics released FY2025 earnings on March 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.4599 (forecast USD -1.975)

Larimar Therapeutics Reports Loss And Receives FDA Breakthrough Therapy Designation

Larimar Therapeutics Announces Stock Issuance, Leading to Price Decline

Larimar Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6091 (forecast USD -0.403)

Larimar Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.4758

Larimar Therapeutics reports Q3 operating expenses of $49.5M

Larimar Therapeutics Announces Positive Clinical Data for nomlabofusp for Friedreich's Ataxia

Li Recommends Healthcare Stocks; Larimar Therapeutics Gets Buy Rating

Wolleben Maintains Strong Buy Rating for Larimar Therapeutics, With a Target Price of $17.25

Argyrides Rates Larimar Therapeutics with a Target Price of $18

Larimar Therapeutics released FY2025 Q2 earnings on August 14 (EST), actual EPS USD -0.41 (forecast USD -0.4766)

Larimar Therapeutics released FY2025 Semi-Annual earnings on August 14 (EST), with actual revenue of USD 0 and EPS of USD -0.8666

Larimar Therapeutics Receives 'Buy' Consensus Rating

Wedbush Maintains Rating for Larimar Therapeutics

Larimar Therapeutics Updates Friedreich's Ataxia Treatment Plan Based on FDA Recommendations

Larimar Therapeutics Inc announces regulatory update for Nomlabofusp project

Larimar Therapeutics Short Interest Rises 64.7%

Larimar Therapeutics Holds Annual Shareholders Meeting

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

LRMR

Larimar Therapeutics shareholders approved governance and capital structure changes during the 2026 Annual Meeting, including the election of Class III directors and an increase in authorized common stock from 115 million to 215 million shares. The board committed to annual advisory votes on executive pay, reflecting strong investor support. Despite a recent analyst rating of 'Buy' with a $12.00 price target, concerns remain regarding the company's financial performance and cash burn.

Tip Ranks

Larimar Shareholders Approve Governance and Capital Structure Changes

Larimar Therapeutics shares are trading lower. The company reported Q1 EPS results.

benzinga_article

Earnings Watch

Larimar Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Larimar Therapeutics (NASDAQ:LRMR) is set to announce its Q4 2025 earnings on March 30, with analysts predicting a loss of $0.41 per share. The company recently reported a loss of $0.73 per share for the previous quarter, missing estimates. The stock is currently trading at $4.49, with a market cap of $466.42 million. Insider James E. Flynn purchased 5 million shares, increasing his stake significantly. Analysts have mixed ratings, with a consensus "Buy" and a target price of $16.43.

Market Beat

Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday

Larimar Therapeutics (NASDAQ:LRMR) shares rose 8.2% after Wedbush upgraded its price target from $12.00 to $13.00, maintaining an outperform rating. The stock traded at $4.83, with a significant drop in trading volume. Other brokerages have also issued ratings, with a consensus rating of "Buy" and an average price target of $16.43. Insider trading saw Director James E. Flynn purchase 5 million shares. Institutional investors have increased their stakes, with 91.92% of shares owned by hedge funds. The company focuses on treatments for rare diseases, with its lead product in clinical trials.

Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade

Larimar Therapeutics | 10-K: FY2025 Revenue: USD 0